You are here


See Current Funding Opportunities - September 13, 2017


FOA PAR17-474, Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low and Middle- Income Countries (LMICs)
Seeks to stimulate new and impactful research towards the development of stigma reduction interventions leading to better outcomes for the prevention and treatment of HIV/AIDS and on the quality of life of People Living with HIV/AIDS (PLWH) in LMICs. Please click below for more information.


PAR-17-471, Detection of HIV for Self-Testing (R61/R33)
Publication date:  August 25, 2017
Due dates:  December 6, 2017, December 6, 2018, and December 6, 2019 (one receipt date per year)
Purpose:  NIAID and NIMH are encouraging grant applications for bi-phasic developmental, proof-of-concept research focused on innovative strategies to detect HIV within the first two weeks of infection or to monitor viral rebound after stopping or developing resistance to antiretroviral therapy. The goal is to develop simple diagnostic tools that would be feasible for a self-testing platform to allow untrained individuals to detect HIV.
Proposed research projects should establish proof-of-concept for simple qualitative or semi-quantitative diagnostic assays that directly detect HIV (RNA, DNA, and/or protein) or other biomarkers that reliably correlate with viral load or rebound. Such assays would complement existing self-testing tools that detect the host antibody response to HIV. Research objectives may include either the initial development of a novel technology or adaptation of an emerging technology to detect HIV in a self-test platform. Interdisciplinary collaborations that include biomedical, physical, and behavioral sciences are highly encouraged.


HIV/HCV Co-Infections in Substance Abusers (R01)
Funding Type: NIDA
Amount: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Release Date: June 13, 2017
Due Date: September 7 2017 and January 7, 2018 , by 5:00 PM local time of applicant organization.
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to fill gaps in our understanding of (a) the impact of substance abuse on HIV, HIV/HCV co-infection associated disease progression, (b) the pathogenic interactions between HIV and hepatitis C virus, (c) hepatic and non-hepatic co-morbidities associated with HIV/HCV-co-infections in people with substance abuse disorders (SUDs), and (d) the effectiveness of interferon-free direct acting antiviral (DAAs) drug regimens to treat HIV/HCV co-infections in people with SUDs. This FOA is informed by priority area in the NIH HIV/AIDS Research Priorities and Guidelines for Determining AIDS Funding: and the HHS National Viral Hepatitis Action Plan 2017-2020:


New NCI RFA : RFA-CA-17-030: HIV/AIDS and the Tumor Niche (R01)


2017 CFAR Administrative Supplements

Each CFAR can submit ONE application.  The Duke CFAR has an internal review process to submit the most competitive application, so if you are interested in submitting, please reply to this email with a few sentences on the topic.

If you are interested in applying for a CFAR Supplement, please reply by Friday, March 31st.


Dear CFAR Directors, Administrators, and Investigators,

The NIH is interested in supplement applications from CFARs in the following scientific area:

Effect of the Opioid Epidemic on HIV/HCV Infection in Rural and Other Non-urban America (max $150K DC)

Click here for the CFAR supplement announcement for more details on the above scientific area of interest.   

The key aspects of this funding opportunity are:

  • The deadline for applications to be received at NIAID is May 22, 2017
  • Budget requests vary depending on the scientific area 
  • Funding will be for one year                                                               
  • Project directors must be early career investigators or established investigators in non-HIV fields who have never received an R01 in HIV/AIDS
  • One application is allowed per CFAR per scientific area of interest
  • The earliest anticipated start date is 6/30/17 but may be delayed due to administrative issues

Please note that the number of applications that will be funded for this administrative supplement announcement will be based on funding availability, scientific merit, and program balance.  Applications must align with the NIH HIV/AIDS research priorities (NOT-OD-15-137).


Sustained Training in Aging and HIV Research (STAHR) Program

Please follow this link for more information.


HIV and Aging RFA for 2017

The purpose of this funding mechanism is to promote aging research among the CFAR investigators and engage OAIC researchers in the field of HIV.
Two pilot grants will be awarded with funding up to $50,000 total costs.

  • Any faculty investigator. (Post-Doc Fellows need to be a faculty member by July 1, 2017.)
  • Deadline for Concepts is January 27th, 2017

Flyer - PDF


CFAR-MEDx Small Grant

Applicants may request up to $60,000 in total direct costs for 1 year.

  • Applications are due by May 1, 2017 at 5:00 PM
  • Faculty level position is required to apply

Request for Proposals - DOC
Cover Letter - DOC
Checklist - DOC


NIH new FOA on phylodynamic tracking of HIV transmission (R01)

New funding opportunity announcement:  PAR-17-048: Phylodynamic Tracking of HIV Transmission (R01). Current set-aside funds for this initiative are $4.39 million, and applications for the first round of funding will be due March 15, 2017.

Please contact Dr. Lillian Kuo ( with any questions about applying to this PAR.


Apply now for the UCSF CAPS Visiting Professors Program

The UCSF Center for AIDS Prevention Studies (CAPS) has a Visiting Professors program to train investigators in conducting research with ethnic minority communities. The VP Program is designed to assist investigators already conducting HIV-prevention research with minority communities to improve their programs of research and obtain additional funding for their work. It includes a 6-week summer residency, pilot funding, and other mentorship and career development opportunities. More information is described below and at their website:


Nicotinic Immune Modulation in the Presence of HIV-1 Infection (R01)
National Institute on Drug Abuse
Application Receipt Date(s): January 17, 2017 by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

  • The FOA encourages the submission of research project applications to determine nicotine’s modulatory effects on peripheral and central immune system functions in the presence of HIV-1 infection.  Specifically, NIDA is particularly interested in projects exploring the ability of nicotine to produce anti-inflammatory and protective effects, and the translational potential of the new knowledge in attenuating HIV-induced pathologies and HIV-associated CNS complications such as neurological/cognitive disorders.   


New RFAs: HIV, HCV and Related Comorbidities in Rural Communities Affected by Opioid Injection Drug Epidemics in the United States: Building Systems for Prevention, Treatment and Control

NIDA/NIH has just released 2 new RFAs (related to each other) to address the rural opioid epidemic and its infectious disease consequences. This is a unique collaboration with CDC, SAMHSA & the Appalachian Regional Commission. RFA-DA-17-014 is for multi-stage projects in communities; RFA-DA-17-023 is for a laboratory. There is reference to FAQ—the link is not yet live in the RFAs, but the link does work and here it is for your convenience:

See the links below for the RFAs:   Application due date: January 10, 2017   Application due date: January 10, 2017


A new AIDS and cancer funding announcement was published in the NIH Guide. 


Here are the links for "High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers: (R01)
Open Date: December 7, 2016
Deadline: January 7, 2017
Expiration Date: September 8, 2019 (R21)
Open Date: December 7, 2016
Deadline: January 7, 2017
Expiration Date: September 8, 2019


New RFAs from NICHD


Understanding STI Co-Infection In At Risk and HIV Infected Adolescents and Young Adults (R01)


Understanding STI Co-Infection In At Risk and HIV Infected Adolescents and Young Adults (R21)

If there are any questions on these RFA, please contact the assigned scientific contacts below:

Nahida Chakhtoura, MD, MsGH
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Telephone: 301-435-6872 

Bill G. Kapogiannis, MD
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Telephone: 301-402-0698


For clinical data, behavioral data, and biospecimens from the mSTUDY Biorepository

NIH HIV/AIDS Research Priorities and Guidelines for Determining AIDS Funding

New RFP from the CNIHR Pilot Awards Program

New Biosketch Format - Doc

Duke Website and Newsletter offer extensive list of funding opportunities.

Duke’s Office of Research Support website provides an extensive database of funding opportunities of interest to the Duke Community. The list is searchable by discipline, eligibility, sponsor, etc.  

To view a list of funding opportunities:

The Office of Research Support highlights new funding opportunities each week through its newsletter, which is published on Monday morning. The newsletter publishes new and recently updated announcements of federal and private funding for research, fellowships, curriculum, and program development.  

Subscribe to receive the newsletter:


The CFAR issues 2 RFP's per year (Spring and Fall).  Additional RFP's may be issued in collaboration with our Strategic Partners or to support Emerging Opportunities.

The intent of a CFAR Developmental Core is to support scientific studies for a period of 1 year to develop preliminary data for peer-reviewed research applications.  Four general areas are eligible for support through the Developmental Core:

  • Investigators who are new to HIV/AIDS research and have not previously received independent research awards such as an R01 in HIV/AIDS research
  • Feasibility Studies
  • Emerging research opportunities
  • HIV/AIDS research activities of newly recruited faculty

Additional information regarding eligibility:

  • High priority for developmental awards will be given to junior faculty. 
  • The CFAR Development Core may be used to fund a collaborative study that encompasses two different scientific disciplines that may not have collaborated previously. 
  • Graduate students lacking a terminal degree are not eligible. 
  • Fellows (postdoctoral fellows, clinical fellows) become eligible to apply for funding after completing at least 6 months of their fellowship. 
  • Prior approval from NIH Program Staff is required for developmental awards to senior investigators.
  • The use of the CFAR Cores for development and implementation of your proposal is strongly encouraged.
  • The CFAR Executive Committee is willing to consider funding meritorious CFAR Small Grant applications from investigators who have previously received CFAR Small Grant awards if:
    1. the previous CFAR Small Grant award was productive (i.e., resulted in peer-reviewed publications and/or subsequent funding)
    2. the “new” CFAR Small Grant application is in a research area different than the originally funded proposal (i.e. not an extension of the original work), and
    3. the new application receives a fundable score. 
  • Previous CFAR Small Grant recipients must have pre-approval from CFAR Developmental Core Director ( before submitting a proposal.